Please assess the completion status of the following clinical trial:

Trial Title: Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female infant of between 6 and 12 weeks of age at the time of first vaccination.~* Written informed consent obtained from the parent(s) or guardian(s) of the subject~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~* Born to a mother who is hepatitis B surface antigen (HBsAg) negative and human immunodeficiency virus (HIV) negative.~* Born after a normal gestation period (between 36 and 42 weeks).~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~Exclusion Criteria:~* Bacillus Calmette-Guérin tuberculosis vaccine (BCG) administration within one week of proposed administration of a study vaccine.~* Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth~* Any chronic drug therapy to be continued during the study period.~* Previous vaccination with diphtheria, tetanus, pertussis, Haemophilus influenzae type b or hepatitis B vaccines.~* Major congenital abnormality.~* Serious acute or chronic illness determined by clinical, physical examination and laboratory screening tests~* Any medically diagnosed or suspected immunodeficient condition based on medical history and physical examination~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* History of any neurological disorders or seizures.~* Maternal death.~* Hemoglobin \< 80 g/L~* Simultaneous participation in any other clinical trial.~* Same sex twin~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trialModerate malnutrition at screening

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- RTS,S/AS02D Group (Type: EXPERIMENTAL): Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of RTS,S/AS02D at days 14, 44 and 74 and a 3-dose vaccination course of TETRActHib™ vaccine at days 0, 30 and 60. The RTS,S/AS02D vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.
- Engerix-B Group (Type: ACTIVE_COMPARATOR): Subjects aged between 6 and 12 weeks at the time of first vaccination received by intramuscular injection a 3-dose vaccination course of Engerix-B® vaccine at days 14, 44 and 74 and a 3-dose of TETRActHib™ vaccine at days 0, 30 and 60. The Engerix-B® vaccine was administered in the left anterolateral thigh, and the TETRActHib™ vaccine in the right anterolateral thigh.

Based on this trial design, predict the completion outcome and termination type (if applicable).